


## NT219

<b>Cat. No.:</b>	HY-145935
<b>CAS No.:</b>	1198078-60-2
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>14</sub> BrNO <sub>5</sub> S
<b>Molecular Weight:</b>	412.26
<b>Target:</b>	Insulin Receptor; STAT
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK; JAK/STAT Signaling; Stem Cell/Wnt
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

### Description

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases<sup>[1]</sup>.

## REFERENCES

[1]. Alberto Bessudo, et al. A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA